Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CDA | P32320 | 1/20 | 0.41 |
| ▸ | SLC29A1 | Q99808 | 2/20 | 0.38 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.38 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.38 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.38 |
| ▸ | ADK | P55263 | 2/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | MTOR | P42345 | 1/20 | 0.36 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.36 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.36 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15607846 | 0.88 | MAPT (0.54) | SLC5A2MAPTCDASLC29A1SLC28A1 | |
| SCHEMBL16367380 | 0.87 | MAPT (0.41) | SLC5A2MAPTCDASLC29A1SLC28A1 | |
| SCHEMBL16367347 | 0.82 | L3MBTL1 (0.41) | SLC5A2ADORA3 | |
| SCHEMBL15607860 | 0.81 | MAPT (0.39) | MAPTCDAADORA3 | |
| SCHEMBL16367416 | 0.78 | LMNA (0.36) | MAPTLMNATHRB | |
| SCHEMBL16367403 | 0.78 | L3MBTL1 (0.38) | ADORA3 | |
| SCHEMBL16367320 | 0.78 | ADORA3 (0.41) | MAPTCDASLC29A1SLC28A3ADK | |
| SCHEMBL26554460 | 0.75 | MAPT (0.48) | SLC5A2MAPTCDASLC29A1SLC28A1 | |
| SCHEMBL11934657 | 0.73 | SLC29A1 (0.42) | SLC29A1ADORA3LMNATHRBMTOR | |
| SCHEMBL11934656 | 0.73 | SLC29A1 (0.42) | SLC29A1ADORA3LMNATHRBMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150010474-A1 | Compounds And Methods For Selective Imaging And/Or Ablation | AUCKLAND UNISERVICES LTD (NL) | 2015-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150010474-A1 | Compounds And Methods For Selective Imaging And/Or Ablation | CBR1, CBR3, BLVRB | SLC5A2 722/4885MAPT 3982/4885CDA 1189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.